Corticosteroids in Lupus

Rheumatic Disease Clinics of North America

Volumn 42, Issue 1, 2016, Pages 47-62

  Kasturi, Shanthini ^a   Sammaritano, Lisa R ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Corticosteroids; Glucocorticoids; Methylprednisolone; Prednisone; Systemic lupus erythematosus

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID DERIVATIVE; WARFARIN; CORTICOSTEROID; GLUCOCORTICOID;

ACNE; ADVERSE DRUG REACTION; ATHEROSCLEROSIS; AVASCULAR NECROSIS; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR DISEASE; COMORBIDITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EYE DISEASE; FRACTURE; GASTRITIS; GASTROINTESTINAL DISEASE; GLAUCOMA; HEART DISEASE; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOPATHOGENESIS; INFECTION; LACTATION; LOW DRUG DOSE; LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; MYOPATHY; OBESITY; OSTEOPOROSIS; PEPTIC ULCER; PREGNANCY; PRIORITY JOURNAL; PURPURA; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN BRUISING; SKIN MANIFESTATION; STRIA; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; WEIGHT GAIN; WOUND HEALING IMPAIRMENT; BONE NECROSIS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; LUPUS ERYTHEMATOSUS, SYSTEMIC; MUSCLE DISEASE;

ADRENAL CORTEX HORMONES; CARDIOVASCULAR DISEASES; CATARACT; COMORBIDITY; DIABETES MELLITUS; GLAUCOMA; GLUCOCORTICOIDS; HUMANS; HYPERTENSION; INFECTION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MUSCULAR DISEASES; OSTEONECROSIS; OSTEOPOROSIS; PEPTIC ULCER;

EID: 84961275892     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.08.007     Document Type: Review

References (60)

1. Baehr G., Soffer L.J. Treatment of disseminated lupus erythematosus with cortisone and adrenocorticotropin. Bull N Y Acad Med 1950, 26:229-234.
2. Dubois E.L., Commons R.R., Starr P., et al. Corticotropin and cortisone treatment for systemic lupus erythematosus. J Am Med Assoc 1952, 149:995-1002.
3. Dubois E.L. Prednisone and prednisolone in the treatment of systemic lupus erythematous. J Am Med Assoc 1956, 161:427-433.
4. Gladman D.D., Urowitz M.B., Rahman P., et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003, 30(9):1955-1959.
5. Zonana-Nacach A., Barr S.G., Magder L.S., et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000, 43(8):1801-1808.
6. Mosca M., Tani C., Carli L., et al. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011, 29(6):S126-S129.
7. Albert D.A., Hadler N.M., Ropes M.W. Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus. Arthritis Rheum 1979, 22(9):945-953.
8. Buttgereit F., da Silva J.A., Boers M., et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002, 61(8):718-722.
9. Luijten R.K., Fritsch-Stork R.D., Bijlsma J.W.J., et al. The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmun Rev 2013, 12(5):617-628.
10. Zhou W., Yang C. The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients. Lupus 2009, 18(9):807-812.
11. Rovin B., Tang Y., Sun J., et al. Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy. Kidney Int 2005, 68(2):747-759.
12. Shapira Y., Weinberger A., Wysenbeek A. Lymphadenopathy in systemic lupus erythematosus. Prevalence and relation to disease manifestations. Clin Rheumatol 1996, 15(4):335-338.
13. Kamen D.L., Zollars E.S. Corticosteroids in Lupus Nephritis and Central Nervous System (CNS) Lupus. Rheum Dis Clin N Am 2016, in press.
14. Blanford A.T., Murphy B.E. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 1977, 127(3):264-267.
15. Østensen M., Khamashta M., Lockshin M., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006, 8(3):209.
16. Ost L., Wettrell G., Bjorkhem I., et al. Prednisolone excretion in human milk. J Pediatr 1985, 106(6):1008-1011.
17. Park-Wyllie L., Mazzotta P., Pastuszak A., et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000, 62(6):385-392.
18. Bay Bjorn A.M., Ehrenstein V., Hundborg H.H., et al. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther 2014, 21(2):73-80.
19. Dörner T., Giesecke C., Lipsky P.E. Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 2011, 13(5):243.
20. Crispin J.C., Kyttaris V.C., Terhorst C., et al. T cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6(6):317-325.
21. Knight J.S., Kaplan M.J. Lupus neutrophils. Curr Opin Rheumatol 2012, 24(5):441-450.
22. Leffler J., Martin M., Gullstrand B., et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 2012, 188(7):3522-3531.
23. Ruiz-Irastorza G., Danza A., Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 2012, 51(7):1145-1153.
24. Stahn C., Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008, 4(10):525-533.
25. Strand V, Buttgereit F, McCabe D, et al. A phase 2, randomized, double-blind comparison of the efficacy and safety of PF-04171327 (1, 5, 10, 15 mg QD) vs. 5 and 10 mg prednisone QD or placebo in subjects with rheumatoid arthritis (RA) over 8 weeks followed by a 4-week taper of study drug. In: American College of Rheumatology 2014 Meeting. Boston, MA, November 15-19, 2014. Late-Breaking Abstract L6.
26. Li X., Zhang F.S., Zhang J.-H., et al. Negative relationship between expression of glucocorticoid receptor alpha and disease activity: glucocorticoid treatment of patients with systemic lupus erythematosus. J Rheumatol 2010, 37(2):316-321.
27. Spies C.M., Schaumann D.H.S., Berki T., et al. Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway. Ann Rheum Dis 2006, 65(9):1139-1146.
28. Parker B.J., Bruce I.N. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 2007, 16:387-393.
29. Mackworth-Young C.G., David J., Morgan S.H., et al. A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus. Ann Rheum Dis 1988, 47:496-502.
30. Flanc R.S., Roberts M.A., Strippoli G.F., et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2004, (1). CD002922.
31. Trevisani V., Castro A., Neves Neto J., et al. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2000, (3). CD002265.
32. Edwards J.C., Snaith M.L., Isenberg D. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment. Ann Rheum Dis 1987, 46(10):773-776.
33. Badsha H., Kong K.O., Lian T.Y., et al. Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus 2002, 11(8):508-513.
34. Badsha H., Edwards C.J. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003, 32(6):370-377.
35. Houssiau F., Vasconcelos C., D'Cruz D., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46(8):2121-2131.
36. Walsh M., Jayne D., Moist L., et al. Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis. Lupus 2010, 19:628-633.
37. Du J., Li M., Zhang D., et al. Flow cytometry analysis of glucocorticoid receptor expression and binding in steroid-sensitive and steroid-resistant patients with systemic lupus erythematosus. Arthritis Res Ther 2009, 11(4):R108.
38. Piotrowski P., Burzynski M., Lianeri M., et al. Glucocorticoid receptor beta splice variant expression in patients with high and low activity of systemic lupus erythematosus. Folia Histochem Cytobiol 2007, 45(4):339-342.
39. Zou Y.-F., Xu J.-H., Wang F., et al. Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study. Autoimmunity 2013, 46(8):531-536.
40. Tsujimura S., Saito K., Nakayamada S., et al. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52(6):1676-1683.
41. Guiducci C., Gong M., Xu Z., et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010, 465(7300):937-941.
42. Myles A.B., Schiller L.F., Glass D., et al. Single daily dose corticosteroid treatment. Ann Rheum Dis 1976, 35(1):73-76.
43. Ballou S., Khan M., Kushner I. Intravenous pulse methylprednisolone followed by alternate day corticosteroid therapy in lupus erythematosus: a prospective evaluation. J Rheumatol 1985, 12(5):944-948.
44. Danowski A., Magder L., Petri M. Flares in Lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. J Rheumatol 2006, 33(1):57-60.
45. Kuhn A., Ruland V., Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options: part I. J Am Acad Dermatol 2011, 65(6):e179-e193.
46. Bruce I.N. "Not only. . .but also": factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44(12):1492-1502.
47. Gladman D.D., Ginzler E., Goldsmith C., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996, 39(3):363-369.
48. Thamer M., Hernán M., Zhang Y., et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009, 36(3):560-564.
49. Toloza S.M., Uribe A.G., McGwin G., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50(12):3947-3957.
50. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145(5):408-415.
51. Magder L.S., Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012, 176(8):708-719.
52. Roman M.J., Shanker B.-A., Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.
53. Ruiz-Irastorza G., Olivares N., Ruiz-Arruza I., et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009, 11(4):R109.
54. Ramsey-Goldman R., Dunn J.E., Huang C.F., et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999, 42(5):882-890.
55. Hromadkova L., Soukup T., Vlcek J. Important drug interactions in patients with rheumatic disorders: interactions of glucocorticoids, immunosuppressants, and antimalarial drugs. Drugs Today (Barc) 2012, 48(8):545-553.
56. Hazlewood K.A., Fugate S.E., Harrison D.L. Effect of oral corticosteroids on chronic warfarin therapy. Ann Pharmacother 2006, 40:2101-2106.
57. Lebrun-Vignes B., Archer V.C., Diquet B., et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001, 51:443-450.
58. Lam S., Partovi N., Ting L.S.L., et al. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?. Ann Pharmacother 2008, 42:1037-1047.
59. Duru N., Van der Goes M., Jacobs J., et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013, 72(12):1905-1913.
60. Buttgereit F., Mehta D., Kirwan J., et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013, 72(2):204-210.